-
Ivermectin Research: From Target Engagement to Evidence
2026-09-27
Ivermectin is a broad-spectrum anti-parasitic agent whose research value depends on more than a visible phenotype. This article connects compound handling and assay design with a pancreatic cancer study, while clearly separating useful experimental lessons from unsupported claims of cross-domain activity.
-
DiscoveryProbe Stem Cell Compound Library Plus Workflow
2026-09-26
Use a curated set of 280 pathway-active compounds to compare stem-cell phenotypes, probe signaling, and prioritize candidates for follow-up. A published schistosome screen illustrates how high-content measurement of stem-cell proliferation can reveal effects that morphology or motility alone may miss.
-
Masitinib (AB1010): Practical Research Workflow
2026-09-26
Masitinib (AB1010) is a DMSO-soluble tyrosine kinase inhibitor for focused studies of KIT, PDGFRα/β, mast-cell responses, and KIT-mutant cellular models. It is not suited to aqueous or ethanol-based formulations, broad-spectrum kinase profiling, or clinical treatment decisions without separate evidence and validation.
-
From Citrate Chemistry to Reproducible SERS Design
2026-09-25
Reproducible SERS depends on controlling nanostructure architecture as well as experimental chemistry. This article examines what a polymer pen lithography study establishes, where Sodium citrate may serve as a carefully qualified workflow variable, and how translational teams can separate demonstrated results from testable hypotheses.
-
GSK J4 HCl: Workflows for JMJD3 Inhibition
2026-09-25
Use GSK J4 HCl to test how H3K27 demethylation influences inflammatory signaling, chromatin state, and cancer-cell phenotypes. This practical guide connects the compound’s cellular prodrug behavior with an influential decidual study, while clarifying what the evidence does—and does not—establish.
-
Candida krusei Phases and BMEC Apoptosis Signaling
2026-09-24
An in-vitro study compared how yeast- and hypha-phase Candida krusei relate to apoptosis and signaling responses in bovine mammary epithelial cells. The paper reports differences in the predominant apoptosis pathways and involvement of TLR/ERK and JNK/ERK signaling.
-
WAY-100635 in 5-HT1A Pain-Affect Research
2026-09-24
Use WAY-100635 to test whether 5-HT1A receptor signaling contributes to pain-related sensory and affective outcomes—not to assume that a serotonergic mechanism has already been proven. This workflow connects selective receptor pharmacology with recent cannabidiol findings while emphasizing controls, assay fit, and interpretation limits.
-
From MIC to Resistance: Ceftolozane Sulfate
2026-09-23
Ceftolozane sulfate is more than a susceptibility-test reagent: it enables a connected view of PBP-mediated killing, adaptive resistance, and PK/PD exposure. This article translates resistance-modeling evidence into practical assay and translational study decisions.
-
LINC01278, mTOR, and Autophagy in Uveal Melanoma
2026-09-23
The reference study identifies LINC01278 as an autophagy-related long noncoding RNA that suppresses uveal melanoma progression through inhibition of the mTOR signaling pathway. Its combination of bioinformatic screening, pharmacological pathway perturbation, cellular assays, and xenograft validation provides a mechanistic framework for studying the LINC01278–mTOR–autophagy axis.
-
EZ Cap™ Human PTEN mRNA (ψUTP) Workflow
2026-09-22
Build reproducible PTEN-expression assays with Cap1, pseudouridine-modified in vitro transcribed mRNA designed for strong mammalian translation and reduced innate immune signaling. The workflow connects direct transfection experiments with nanoparticle-enabled models of PI3K/Akt-driven trastuzumab resistance.
-
Naked Mole-Rat cGAS, DNA Repair, and Healthy Aging
2026-09-21
The reference study identifies an evolutionary reversal in naked mole-rat cGAS: four amino acid changes convert a DNA-damage regulator that suppresses homologous recombination in humans and mice into a factor that promotes repair. The work connects altered cGAS ubiquitination, prolonged chromatin retention, FANCI–RAD50 recruitment, reduced senescence, and improved aging phenotypes across cellular, fly, and mouse models.
-
Mitoxantrone Targets the ERα DBD–LBD Interface
2026-09-21
Wang et al. identify mitoxantrone as an allosteric ligand for the estrogen receptor α DNA-binding domain–ligand-binding domain interface, inducing receptor redistribution and proteasomal degradation independently of its DNA damage activity. The study provides a resistance-focused framework for testing ERα degradation, mutant receptor inhibition, and interdomain communication in breast cancer models.
-
Trilaurin Digestion Protects Desmopressin
2026-09-20
This 2014 study introduced an in vitro model that coupled triglyceride lipolysis with proteolytic degradation to examine oral delivery of peptide drugs from solid lipid microparticles. It showed that Trilaurin, or Glycerol Tridodecanoate, can alter desmopressin release and protect the peptide during enzymatic challenge, highlighting digestion as a formulation-design variable.
-
Olive Biophenols in Alzheimer’s Disease Models
2026-09-19
The reference study combined amyloid aggregation assays, SH-SY5Y neuroblastoma experiments, and an APPswe/PS1dE9 mouse model to examine whether olive-derived biophenols can reduce Aβ-related toxicity and plaque deposition. Its main contribution is linking specific compounds, particularly oleuropein, verbascoside, and rutin, with anti-amyloidogenic and neuroprotective effects while also identifying bioavailability and blood–brain barrier penetration as unresolved translational questions.
-
LDH Cytotoxicity Assay Kit: Practical Workflow
2026-09-19
The LDH Cytotoxicity Assay Kit (SKU K2228) provides a culture-medium readout of cell membrane damage by measuring released lactate dehydrogenase activity. It is appropriate for in vitro cell cytotoxicity measurement and supportive apoptosis detection workflows, but LDH release alone cannot identify the death mechanism or establish an in vivo outcome.